日本ケミファの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/01/25 | 1,723 | 1,738 | 1,709 | 1,737 | +13 | +0.8% | 8,900 |
2023/01/24 | 1,714 | 1,725 | 1,702 | 1,724 | +10 | +0.6% | 5,700 |
2023/01/23 | 1,718 | 1,729 | 1,703 | 1,714 | -1 | -0.1% | 4,000 |
2023/01/20 | 1,714 | 1,716 | 1,704 | 1,715 | -3 | -0.2% | 2,500 |
2023/01/19 | 1,700 | 1,718 | 1,695 | 1,718 | +25 | +1.5% | 5,000 |
2023/01/18 | 1,675 | 1,704 | 1,675 | 1,693 | +18 | +1.1% | 4,900 |
2023/01/17 | 1,677 | 1,679 | 1,651 | 1,675 | -2 | -0.1% | 5,000 |
2023/01/16 | 1,671 | 1,680 | 1,670 | 1,677 | +6 | +0.4% | 3,200 |
2023/01/13 | 1,662 | 1,678 | 1,662 | 1,671 | +13 | +0.8% | 3,900 |
2023/01/12 | 1,673 | 1,674 | 1,657 | 1,658 | -23 | -1.4% | 2,900 |
2023/01/11 | 1,677 | 1,691 | 1,668 | 1,681 | -6 | -0.4% | 5,000 |
2023/01/10 | 1,663 | 1,687 | 1,660 | 1,687 | +25 | +1.5% | 4,200 |
2023/01/06 | 1,645 | 1,663 | 1,645 | 1,662 | +21 | +1.3% | 2,100 |
2023/01/05 | 1,647 | 1,649 | 1,640 | 1,641 | ±0 | ±0% | 1,700 |
2023/01/04 | 1,648 | 1,650 | 1,641 | 1,641 | -16 | -1% | 3,000 |
2022/12/30 | 1,644 | 1,660 | 1,642 | 1,657 | +13 | +0.8% | 3,700 |
2022/12/29 | 1,634 | 1,644 | 1,634 | 1,644 | +10 | +0.6% | 1,900 |
2022/12/28 | 1,642 | 1,642 | 1,634 | 1,634 | -17 | -1% | 8,100 |
2022/12/27 | 1,645 | 1,655 | 1,644 | 1,651 | +6 | +0.4% | 6,000 |
2022/12/26 | 1,657 | 1,657 | 1,639 | 1,645 | +2 | +0.1% | 6,600 |
2022/12/23 | 1,651 | 1,663 | 1,635 | 1,643 | -17 | -1% | 8,200 |
2022/12/22 | 1,652 | 1,660 | 1,652 | 1,660 | +8 | +0.5% | 1,700 |
2022/12/21 | 1,675 | 1,676 | 1,652 | 1,652 | -23 | -1.4% | 4,300 |
2022/12/20 | 1,659 | 1,690 | 1,659 | 1,675 | +4 | +0.2% | 5,300 |
2022/12/19 | 1,675 | 1,680 | 1,661 | 1,671 | -4 | -0.2% | 5,300 |
2022/12/16 | 1,685 | 1,685 | 1,675 | 1,675 | -15 | -0.9% | 5,800 |
2022/12/15 | 1,682 | 1,691 | 1,682 | 1,690 | +8 | +0.5% | 700 |
2022/12/14 | 1,668 | 1,682 | 1,668 | 1,682 | +14 | +0.8% | 1,800 |
2022/12/13 | 1,685 | 1,685 | 1,663 | 1,668 | -2 | -0.1% | 4,200 |
2022/12/12 | 1,698 | 1,700 | 1,660 | 1,670 | +8 | +0.5% | 9,000 |
2022/12/09 | 1,655 | 1,662 | 1,654 | 1,662 | +11 | +0.7% | 4,800 |
2022/12/08 | 1,682 | 1,682 | 1,651 | 1,651 | -23 | -1.4% | 6,000 |
2022/12/07 | 1,680 | 1,690 | 1,674 | 1,674 | -6 | -0.4% | 6,400 |
2022/12/06 | 1,701 | 1,710 | 1,680 | 1,680 | -31 | -1.8% | 3,700 |
2022/12/05 | 1,681 | 1,713 | 1,681 | 1,711 | +25 | +1.5% | 5,000 |
2022/12/02 | 1,683 | 1,699 | 1,680 | 1,686 | -14 | -0.8% | 7,800 |
2022/12/01 | 1,698 | 1,704 | 1,681 | 1,700 | +1 | +0.1% | 10,100 |
2022/11/30 | 1,707 | 1,709 | 1,698 | 1,699 | -1 | -0.1% | 3,900 |
2022/11/29 | 1,705 | 1,732 | 1,700 | 1,700 | -4 | -0.2% | 9,000 |
2022/11/28 | 1,699 | 1,718 | 1,691 | 1,704 | +14 | +0.8% | 11,700 |
2022/11/25 | 1,685 | 1,690 | 1,681 | 1,690 | +9 | +0.5% | 6,200 |
2022/11/24 | 1,668 | 1,682 | 1,668 | 1,681 | +16 | +1% | 10,900 |
2022/11/22 | 1,666 | 1,669 | 1,656 | 1,665 | +3 | +0.2% | 7,100 |
2022/11/21 | 1,663 | 1,663 | 1,655 | 1,662 | -1 | -0.1% | 4,100 |
2022/11/18 | 1,667 | 1,667 | 1,655 | 1,663 | +14 | +0.8% | 1,600 |
2022/11/17 | 1,660 | 1,684 | 1,649 | 1,649 | -6 | -0.4% | 2,400 |
2022/11/16 | 1,671 | 1,671 | 1,653 | 1,655 | -16 | -1% | 5,400 |
2022/11/15 | 1,685 | 1,685 | 1,669 | 1,671 | -15 | -0.9% | 2,400 |
2022/11/14 | 1,697 | 1,697 | 1,667 | 1,686 | +6 | +0.4% | 11,100 |
2022/11/11 | 1,686 | 1,690 | 1,673 | 1,680 | -6 | -0.4% | 4,900 |
451~
500
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
ティムス | 20,500円 | - | - | 0.00% | - | 2.78倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補品を香港拠点ジーシンに導出 |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
チャート関連のコラム